Pharmaceuticals : classes, therapeutic agents, areas of application

목차 (Table of Contents)

• [Volume. 1]----------
• CONTENTS
• Introduction = 1
• 1 The Pharmaceutical Industry = 3
• 1. Introduction = 3
• 2. Companies. Markets, and Products = 5
• 3. References = 9
• Cardiovascular Drugs = 11
• 2 Cardioactive and Vasoactive Drugs = 13
• 1. General Survey = 14
• 2. Classification = 16
• 3. Antiatherosclerotic Drugs(Survey) = 17
• 4. Blood Lipid Affecting Drugs = 19
• 5. Platelet Affecting Drugs = 30
• 6. Blood Flow Affecting Drugs = 44
• 7. References = 51
• 3 Blood Pressure Increasing Agents = 59
• 1. Introduction = 59
• 2. Sympathomimetics = 60
• 3. Substances Having Other Modes of Action = 65
• 4. References = 67
• 4 Antihypertensive Agents = 69
• 1. Introduction = 70
• 2. Diuretics = 70
• 3. Inhibitors of Angiotensin Converting Enzyme = 78
• 4. Inhibitors of the Sympathetic Nervous System = 81
• 5. Smooth Muscle Relaxants = 95
• 6. Perspectives in the Development of Antihypertensive Drugs = 102
• 7. Summary and Conclusions = 103
• 8. References = 103
• 5 Antiarrhythmic Drugs = 115
• 1. Antiarrhythmic Drugs = 115
• 2. Individual Antiarrhythmic Drugs = 124
• 3. References = 134
• 6 Beta Blockers = 137
• 1. Introduction = 137
• 2. Pharmacodynamics = 139
• 3. Pharmacokinetics = 143
• 4. Clinical Uses of β-Adrenoceptor Blocking Drugs = 144
• 5. Side Effects = 150
• 6. Individual β-Blocking Drugs = 152
• 7. References = 160
• 7 Cardiac Glycosides and Synthetic Cardiotonic Drugs = 173
• 1. Introduction = 173
• 2. Cardiac Glycosides = 176
• 3. Nonglvcosidic Inotropic Agents = 191
• 4. References = 197
• 8 Calcium Antagonists = 201
• 1. Introduction = 201
• 2. Sites of Action = 202
• 3. Structure - Activity Relationships = 204
• 4. General Aspects of Chemistry = 207
• 5. References = 213
• 9 Drugs Affecting Circulation = 217
• 1. Introduction = 217
• 2. Anatomy and Physiology of Coronary Circulation = 218
• 3. Nitrates = 222
• 4. β-Receptor Blockers = 225
• 5. Calcium Channel Blockers(Calcium Antagonists) = 227
• 6. Large Coronary Artery Dilators = 230
• 7. Potent Coronary Arteriolar Vasodilators = 231
• 8. References = 232
• 10 Blood = 235
• 1. Introduction = 237
• 2. Composition, Physiology and Chemical Properties of Blood = 238
• 3. Production = 265
• 4. Therapeutic Uses = 270
• 5. Quality and Safety Requirements and Controls, Legal Aspects = 278
• 6. Storage and Transportation = 283
• 7. Economic Aspects = 284
• 8. References = 284
• 11 Diuretics = 289
• 1. Introduction = 289
• 2. Carbonic Anhydrase Blockers = 291
• 3. Saluretics = 292
• 4. Potassium-Retaining Diuretics = 298
• 5. Aquaretics = 300
• 6. Adenosine A1 Receptor Antagonists = 300
• 7. References = 302
• [Volume. 2]----------
• CONTENTS
• Neuropharmaceuticals = 305
• 1 Neuropharmaceutical Agents = 307
• 1. Introduction = 307
• 2. Types of Neural Cells = 308
• 3. Evolution and Organization of the Vertebrate Nervous System = 312
• 4. Techniques for Investigating the Nervous System = 318
• 5. Synaptic Transmission = 327
• 6. References = 338
• 2 Analeptics = 339
• 1. Analeptics = 339
• 2. References = 340
• 3 Analgesics and Antipyretics = 341
• 1. Introduction = 341
• 2. Nonsteroidal Anti-inflammatory Drugs(NSAIDs) = 344
• 3. Centrally Acting Analgesics = 386
• 4. References = 427
• 4 Anesthetics = 435
• 1. Introduction = 435
• 2. Inhalation Anesthetics = 438
• 3. Intravenous Anesthetics = 443
• 4. Combination Anesthetics = 448
• 5. References = 455
• 5 Appetite Suppressants = 457
• 1. Introduction = 457
• 2. Animal and Human Test Procedures = 457
• 3. Mechanism of Action = 458
• 4. Clinical Side Effects = 459
• 5. Phenethylamine Derivatives = 459
• 6. Other Compounds = 466
• 7. Economic Aspects = 466
• 8. References = 467
• 6 Antiepileptic Drugs = 469
• 1. Introduction = 469
• 2. Current Antiepileptic Drugs = 473
• 3. References = 487
• 7 Sedatives = 489
• 1. Introduction = 489
• 2. Sedatives, Antihistamines, and Tranquilizers = 495
• 3. Alcohols and Aldehydes = 497
• 4. Urethanes, Acyclic Urea Derivatives, and Amides = 499
• 5. Cyclic Carboxamides, Carboximides, Cyclic Urea Derivatives, and Related Compounds = 502
• 6. Other Hypnotics = 527
• 7. References = 530
• 8 Local Anesthetics = 539
• 1. Introduction = 539
• 2. Benzoates = 542
• 3. Carboxylic Acid Amides = 545
• 4. Basic Ketones and Ethers = 550
• 5. Nitrogen-Free Local Anesthetics = 552
• 6. References = 552
• 9 Parkinsonism Treatment = 555
• 1. Introduction = 555
• 2. Therapy of Parkinson's Disease = 559
• 3. New Developments = 579
• 4. References = 582
• 10 Antipsychotics／Neuroleptics = 587
• 1. Introduction = 588
• 2. Neuroleptics = 588
• 3. Antidepressants = 610
• 4. Anxiolytics = 634
• 5. Geriatric Drugs = 649
• 6. References = 660
• 11 Skeletal Muscle Relaxants = 667
• 1. Peripherally Acting Muscle Relaxants = 667
• 2. Centrally Acting Muscle Relaxants = 676
• 3. References = 682
• 12 Spasmolytics = 685
• 1. Introduction = 685
• 2. Parasympatholytics(Neurotropic Spasmolytic Agents) = 687
• 3. Musculotropic and Neurotropic Musculotropic Spasmolytic Agents = 698
• 4. Miscellaneous Agents = 706
• 5. Future Prospects = 706
• 6. References = 706
• Gastrointestinal Drugs = 711
• 13 Anti-ulcer Drugs = 713
• 1. Introduction = 713
• 2. Pathophysiology and Therapeutic Concepts = 714
• 3. Drugs = 716
• 4. Prospect for Future Developments = 732
• 5. Relative Drug Assessment = 734
• 6. References = 734
• 14 Antiemetics = 741
• 1. Tropane Alkaloids = 741
• 2. Benzhydryl Derivatives = 742
• 3. Phenothiazine Derivatives = 744
• 4. Metoclopramide = 744
• 5. References = 745
• 15 Gallbladder and Liver Therapeutics = 747
• 1. Choleretics = 748
• 2. Dissolution of Gallstones = 754
• 3. Liver Therapeutics = 761
• 4. References = 773
• 16 Laxatives = 779
• 1. Introduction and History = 779
• 2. Types of Laxatives = 781
• 3. References = 792
• 17 Gastroprokinetic Agents = 793
• 1. Introduction = 794
• 2. The Historical Dopaminergic Theory = 794
• 3. Interactions with the Cholinergic System = 798
• 4. Interactions with 5-HT3 Receptors = 800
• 5. Interactions with 5-HT4 Receptors = 804
• 6. Electrophysiology of 5-HT and Benzamides = 813
• 7. Radioligand Binding Studies = 819
• 8. Conclusions and Unsolved Issues = 821
• 9. References = 822
• 18 Motilin = 835
• 1. Occurrence = 835
• 2. Release = 835
• 3. Biological Effects = 835
• 4. References = 836
• Respiratory Tract = 837
• 19 Cough Remedies = 839
• 1. Introduction = 839
• 2. Antitussives = 840
• 3. Expectorants = 854
• 4. References = 858
• 20 Antiasthmatics = 861
• 1. Introduction = 861
• 2. Bronchodilators(Relievers) = 863
• 3. Antiinflamrnatory Drugs or Controllers(Glucocorticosteroids) = 893
• 4. Antiallergic Therapy = 895
• 5. Antileukotrienes = 896
• 6. Newer Concepts in Asthma Therapy = 897
• 7. References = 898
• 21 Antiallergics = 901
• 1. Introduction = 901
• 2. Antihistamines = 902
• 3. Mast Cell Stabilizing Agents = 933
• 4. Allergen Preparations for Desensitization = 935
• 5. References = 943
• [Volume. 3]----------
• Antiinfectives = 949
• 1 Antibiotics = 951
• 1. Introduction = 952
• 2. Chemotherapeutic Use of Antibiotics = 955
• 3. Classification of Antibiotics = 959
• 4. Antibiotics in Current Use = 1017
• 5. Fermentation = 1073
• 6. Isolation and Purification of Antibiotics ; Quality Specifications = 1084
• 7. Analytical Measurements and Quality Control = 1089
• 8. Economic Aspects = 1093
• 9. References = 1095
• 2 Synthetic Chemotherapeutic Agents = 1107
• 1. Introduction = 1108
• 2. Chemotherapy of Bacterial Infections = 1109
• 3. Chemotherapy of Protozoan Infections = 1146
• 4. Chemotherapy of Viral infections = 1172
• 5. References = 1189
• 3 Antimycotics = 1199
• 1. Introduction = 1199
• 2. Azole Antimycotics = 1201
• 3. Polyene Antimycotics = 1232
• 4. Flucytosine = 1238
• 5. Griseofulvin = 1241
• 6. Ciclopirox = 1244
• 7. Thiocarbamates = 1246
• 8. Allylamines = 1248
• 9. Amorolfine = 1252
• 10. Unspecific Topical Antimycotics = 1254
• 11. Recent Developments and Outlook = 1256
• 12. References = 1256
• 4 Anthelmintics = 1265
• 1. Introduction = 1265
• 2. Parasitic Worms = 1266
• 3. Anthelmintic Drugs = 1277
• 4. References = 1287
• 5 HIV and AIDS Therapeutics = 1291
• 1. Introduction - HIV and AIDS = 1292
• 2. Reverse Transcriptase Inhibitors = 1294
• 3. Protease Inhibitors = 1304
• 4. Emerging Concepts in AIDS Therapy = 1315
• 5. References = 1315
• Endocrine and Metabolic Drugs = 1319
• 6 Steroids = 1321
• 1. Nomenclature = 1321
• 2. Sterols = 1322
• 3. Bile Acids = 1328
• 4. Steroid Hormones = 1330
• 5. Sapogenins = 1332
• 6. Steroid Alkaloids = 1333
• 7. Steroid Lactones = 1335
• 8. References = 1336
• 7 Peptides and Protein Hormones = 1339
• 1. Introduction = 1340
• 2. Gonadoliberin, Thyroliberin, Gonadotropins, Thyrotropin, Inhibin, and Related Hormones = 1348
• 3. Parathvroid Hormone and the Calcitonin Family = 1362
• 4. Corticoliberin - Proopiomelanocortin Cascade = 1369
• 5. Blood Pressure Regulating Peptides = 1388
• 6. Cholecystokinin and Gastrin = 1413
• 7. Secretin Family = 1421
• 8. References = 1449
• 8 Chemical Contraception = 1493
• 1. Introduction = 1493
• 2. Natural Methods = 1493
• 3. Barrier Methods = 1495
• 4. Hormonal Methods = 1497
• 5. Intrauterine Devices(IUDs) = 1506
• 6. Sterilization = 1507
• 7. Contragestational Drugs = 1508
• 8. New Approaches = 1510
• 9. References = 1514
• 9 Thyrotherapeutic Agents = 1519
• 1. Introduction = 1520
• 2. Thyroid Hormones as Therapeutic Agents = 1521
• 3. Thyroid Depressants as Therapeutic Agents = 1524
• 4. References = 1531
• 10 Hormones = 1533
• 1. Introduction = 1535
• 2. Amino Acid Hormones = 1555
• 3. Steroid Sex Hormones = 1564
• 4. Adrenal Steroid Hormones = 1601
• 5. Cholecalciferol = 1636
• 6. References = 1641
• 11 Oral Antidiabetic Drugs = 1653
• 1. Introduction = 1653
• 2. Stimulators of Insulin Secretion = 1654
• 3. Biguanides = 1660
• 4. Inhibitors of Intestinal Carbohydrate Digestion = 1661
• 5. Enhancers of Insulin Action = 1665
• 6. References = 1667
• [Volume. 4]----------
• CONTENTS
• Miscellaneous Drugs = 1669
• 1 Anti-inflammatory-Antirheumatic Drugs = 1671
• 1. Introduction = 1671
• 2. Glucocorticoids = 1675
• 3. Nonsteroidal Anti-inflammatory Drugs and Selective COX-2 Inhibitors = 1676
• 4. Antirheumatic Agents = 1702
• 5. Inhibitors of Tumor Necrosis Factor = 1707
• 6. Natural Products = 1708
• 7. References = 1709
• 2 Drugs Used in Dermatology = 1713
• 1. Introduction = 1713
• 2. Functions and Structure of the Skin = 1714
• 3. Topical Therapy = 1715
• 4. Drugs Used in Dermatology by Class = 1718
• 5. References = 1733
• 3 Gout Remedies = 1737
• 1. Introduction = 1737
• 2. Gout and Hyperuricemia = 1739
• 3. Treatment = 1741
• 4. References = 1749
• 4 Immunotherapy and Vaccines = 1753
• 1. Introduction = 1755
• 2. Bacterial Vaccines = 1764
• 3. Viral Vaccines = 1787
• 4. Vaccines against Parasites = 1805
• 5. Immunotherapy = 1821
• 6. Immunotherapeutic Uses of Monoclonal Antibodies = 1839
• 7. References = 1844
• 5 Cancer Chemotherapy = 1865
• 1. Introduction = 1866
• 2. Antimetabolites = 1868
• 3. Alkylating Agents = 1885
• 4. Anthracyclines = 1897
• 5. Intercalating Anthracenes and Analogs = 1902
• 6. Antitumor Antibiotics Other than Anthracyclines = 1904
• 7. Antitubulin Agents = 1909
• 8. Heavy-Metal Complexes = 1918
• 9. Hormonally Active Anticancer Drugs／Antihormones = 1922
• 10. Signal Transduction Inhibitors = 1937
• 11. Economic Aspects = 1939
• 12. References = 1940
• 6 Interferons = 1957
• 1. Introduction = 1958
• 2. Classification and Origin = 1959
• 3. Biological Activity = 1964
• 4. Mechanism of Action = 1963
• 5. Physicochemical Properties = 1964
• 6. Purification = 1968
• 7. Quality Specifications = 1972
• 8. Clinical Studies = 1975
• 9. References = 1978
• 7 Monoclonal Antibodies = 1981
• 1. Introduction = 1981
• 2. Derivation of Murine Monoclonal Antibodies by Somatic Cell Fusion = 1983
• 3. Human Monoclonal Antibodies = 1987
• 4. Production = 1989
• 5. Purification = 1991
• 6. Monoclonal Antibody Patents = 1993
• 7. Uses = 1994
• 8. References = 1997
• 8 Ophthalmological Agents = 2001
• 1. Introduction = 2002
• 2. Anesthetics = 2002
• 3. Antimicrobial Agents = 2004
• 4. Anti-inflammatory Agents = 2015
• 5. Antiglaucomatous Agents = 2019
• 6. Mydriatics and Cycloplegics = 2026
• 7. Vasoactive(Adrenergic) Agents = 2029
• 8. Diagnostic Agents = 2030
• 9. Dry Eye Medications = 2032
• 10. Miscellaneous Ophthalmic and Contact Lens Preparations = 2035
• 11. References = 2040
• 9 Prostaglandins = 2045
• 1. History = 2045
• 2. Structure, Nomenclature, and Physical Properties = 2046
• 3. Occurrence and Biosynthesis = 2050
• 4. Pharmacological Effects and Uses = 2055
• 5. Syntheses = 2058
• 6. References = 2071
• Related Technology = 2075
• 10 Pharmaceutical Dosage Forms = 2077
• 1. Dosage Forms as Drug Delivery Systems = 2078
• 2. Routes of Administration = 2081
• 3. Types of Dosage Forms = 2085
• 4. Pharmaceutical Excipients = 2101
• 5. Quality Assurance = 2105
• 6. Pharmaceutical Containers = 2106
• 7. Development of the Ideal Drug Delivery System = 2109
• 8. References = 2122
• 11 Drug Testing = 2125
• 1. Preclinical Testing = 2126
• 2. Clinical Trials = 2134
• 3. Quality Control of Pharmaceutical Products = 2140
• 4. References = 2155
• 12 Veterinary Drugs = 2157
• 1. Antibiotics and Antibacterial Drugs = 2158
• 2. Antimycotics = 2171
• 3. Coccidiostats = 2172
• 4. Parasiticides = 2173
• 5. Anti-inflammatory Drugs = 2175
• 6. Respiratory Stimulants = 2179
• 7. Anesthetics = 2180
• 8. Narcotic Agonists and Antagonists = 2182
• 9. Antihistarnines = 2184
• 10. References = 2185
• Index = 2187
• 1. Author Index = 2187
• 2. CAS Registry Number Indes = 2191
• 3. Subject Index = 2211